6,6-diphenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole | 62476-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6,6-diphenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole
• 英文别名: 6,6-Diphenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole；6,6-diphenyl-3,5-dihydro-2H-imidazo[2,1-b][1,3]thiazole
• CAS: 62476-40-8
• 化学式: C₁₇H₁₆N₂S
• 分子量: 280.393
• InChiKey: UMDLYKBETBPFDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6,6-diphenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazol-5-ol 以33%的产率得到
  参考文献：
  名称：

  OKADA K.; KELLEY J. A.; DRISCOLL J. S., J. ORG. CHEM. , 1977, 42, NO 15, 2594-2597

  摘要：

  DOI：

文献信息

• Anthelmintic gel compositions and a method for their preparation at ambient temperatures
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0113397A2

  公开（公告）日：1984-07-18

  This invention relates to aqueous gels, which remain gelatinous in a temperature range as low as -270°C containing dl- or 1-6-phenyl-2,3,5,6-tetrahydro-(-)imidazo [2,1-b]thiazole, acylamino derivatives thereof and pharmaceutically acceptable salts thereof, characterized by gelation and preparation at ambient temperatures (20-60°C), under vacuum, without additionai heating or cooling in their preparation.

  本发明涉及在低至-270°C的温度范围内保持凝胶状的含水凝胶，其中含有dl-或1-6-苯基-2,3,5,6-四氢-(-)咪唑并[2,1-b]噻唑、其酰氨基衍生物及其药学上可接受的盐，其特点是在环境温度（20-60°C）、真空条件下凝胶化和制备，在制备过程中无需额外加热或冷却。
• Intramolecular cyclizations leading to bridgehead bicyclics. 3. 5,5-Diphenyl-2-thiohydantoin derivatives
  作者：Katsuhide Okada、James A. Kelley、John S. Driscoll

  DOI：10.1021/jo00435a012

  日期：1977.7
• [EN] USE OF TETRAMISOLE AND ITS DERIVATIVES AGAINST SPORE PRODUCING MICROORGANISMS<br/>[FR] UTILISATION DE TETRAMISOLE ET DE SES DERIVES DANS LA LUTTE CONTRE DES MICRO-ORGANISMES PRODUISANT DES SPORES
  申请人：BIOPHAGE INC

  公开号：WO2003037331A1

  公开（公告）日：2003-05-08

  The present invention relates to the use of tetramisole or its derivatives as an active agent, in a composition, a biocidal formulation and in methods, for preventing or treating of disease, such as anthrax, caused by a spore producing microorganism, such as Bacillus anthracis, in a human, or in the prevention or inhibition of the growth of such a spore producing microorganism in a human or for inhibiting the biological activity of the spore producing microorganism in a selected area, such as a post office.